Skip to contentZ
Zivo Bioscience, Inc.
Z
ZIVOZivo Bioscience, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00derived— vs Q4 2020 Net Income-$3.14M-$3.14MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Zivo Bioscience, Inc. · CIK 1101026 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,139,024N/M Operating Cash Flowderived-$1,901,524N/M ended Dec 31, 2021 · filed Apr 22, 2022 · 112 d after period end